The Ethics of Reporting and Disseminating Results of Clinical Research Trials

Cancer

Volumn 100, Issue 6, 2004, Pages 1107-1109

  Bell, Jeffrey G ^a,b   Brady, Mark ^c   Copeland, Larry J ^b,d  

^a RIVERSIDE METHODIST HOSPITAL   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Gynecologic Oncology Group   (United States)

^d Ovarian Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ANEMIA; BONE MARROW SUPPRESSION; CLINICAL RESEARCH; CLINICAL TRIAL; DECISION MAKING; ETHICS; GRANULOCYTOPENIA; GYNECOLOGIC CANCER; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEUROTOXICITY; NEUTROPENIA; PATIENT GUIDANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT PLANNING;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CLINICAL TRIALS; HUMANS; INFORMED CONSENT; RESEARCH DESIGN; TRUTH DISCLOSURE;

EID: 1542314296     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20067     Document Type: Review

References (4)

1. Markham M. Informing patients with cancer of 'new findings' that may influence their willingness to participate in research studies [commentary]. Cancer. 2003;98:885-887.
2. Bell JG, Brady M, Lage J, et al. A randomized phase III trial of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: a Gynecologic Oncology Group Study [abstract]. Gynecol Oncol. 2003;85:156.
3. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm Trial: two parallel randomized Phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112.
4. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer - adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003;95:113-125.